3 Reasons Why Investors Undervalue Allergan

Are investors undervaluing Allergan (AGN)? That’s the opinion of Normura analyst Shibani Malhotra in a research note published earlier today in which she argues that at its current price of $315 a share, the drug maker trades roughly 15% below the implied per-share value of its $150 billion merger deal with Pfizer (PFE). What are […]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.